Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Two Formulations of GSK5784283 in Healthy Volunteers
NCT07712393Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of felcorekibart in asthma (2 arms), sponsored by GSK. Primary endpoints: Maximum Observed Concentration and Area Under the Curve from Zero up to 253 Days. Started Jul 2026; status: active, not recruiting.
02
Drugs
felcorekibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07712393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712393.